Anna Sjögren
Chief Tech/Sci/R&D Officer bij EGETIS THERAPEUTICS AB
Profiel
Anna Sjögren is currently the Director-Project & Clinical Development at Egetis Therapeutics AB.
Previously, she worked as the Director-Clinical Operations at OxThera AB from 2013 to 2017.
She received her undergraduate degrees from Karolinska Institutet and the University of Uppsala.
Actieve functies van Anna Sjögren
| Bedrijven | Functie | Begin |
|---|---|---|
| EGETIS THERAPEUTICS AB | Chief Tech/Sci/R&D Officer | - |
Eerdere bekende functies van Anna Sjögren
| Bedrijven | Functie | Einde |
|---|---|---|
OxThera AB
 OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | Corporate Officer/Principal | 01-12-2017 |
Opleiding van Anna Sjögren
| Karolinska Institutet | Undergraduate Degree |
| University of Uppsala | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| EGETIS THERAPEUTICS AB | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
OxThera AB
OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | Health Technology |
